Vyvanse's Generic Is 3 Years Old. Why Is It Still Expensive?
Lisdexamfetamine went generic in August 2023. In 2026 the cash price is still $200+. Here's the documented why, and what people actually pay.
July 26, 2026 · 5 min read
Generic Vyvanse turned three in August, and a month of lisdexamfetamine still retails for $200–360 per GoodRx. A free coupon at the same counter cuts that to about $61. So the practical verdict is simple: never pay the sticker price. The rest of this article explains why the sticker is still that high.
Because by every normal rule it shouldn't be. Patent expires, a dozen manufacturers pile in, the price falls off a cliff within a year or two. Atorvastatin did it. Escitalopram did it. Vyvanse's patent expired on August 24, 2023, and the FDA approved first generics from roughly 14 manufacturers within days, about as much day-one competition as a generic launch ever gets. The cliff never came anyway.
Standard disclaimer, sincerely meant: this is pricing journalism, nothing more. Whether lisdexamfetamine belongs in your life, and at what strength, stays a conversation between you and your prescriber.
The timeline
- August 2023: Patent expires; FDA clears generics from about 14 manufacturers at once (Psychiatric Times, Forbes). This lands in the middle of the amphetamine shortage that started in late 2022.
- 2024–2025: Generics ship, but erratically. Multiple manufacturers report they can't get enough active ingredient. Prices dip, then plateau far above normal generic territory.
- September 2025: The DEA raises the aggregate production quota for lisdexamfetamine by roughly 22% after a manufacturer requests more, with further increases allowed for 2026.
- 2026: ASHP still lists lisdexamfetamine capsules as a current shortage. Amneal and Hikma cite active-ingredient problems, Teva reports limited supply of the 70 mg strength, and Apotex and Lannett report availability. Better than 2023. Not over.
What it costs in mid-2026
| What you're buying | Typical cash price, 30-day supply |
|---|---|
| Brand Vyvanse, retail | ~$300–400+ |
| Generic lisdexamfetamine, retail | ~$200–360 |
| Generic lisdexamfetamine, with a GoodRx-type coupon | ~$61–68 |
Sources: GoodRx lisdexamfetamine page (lowest coupon prices around $61, against an average retail near $310 for the most common version) and GoodRx's Vyvanse pricing. Prices vary by strength and pharmacy, and during a shortage they vary by the week.
Read the table again, because it contains the real scandal. The spread between the retail price and the coupon price at the same counter can be $250. Retail is an opening offer.
Why competition didn't crash the price
Four documented reasons, stacked on top of each other.
1. You can't make more without permission. Lisdexamfetamine is a Schedule II amphetamine. The DEA sets an annual aggregate production quota, a national ceiling on how much can legally be manufactured, and allocates slices of it to individual companies. When demand outran the quota, manufacturers couldn't respond the way generic makers normally do, which is "make more." The DEA's own Federal Register notice adjusting the 2025 quota upward is the paper trail. The ceiling was binding.
2. Approved and shipping are different things. Fourteen-ish approvals sounds like fourteen competitors. In practice, the ASHP shortage entry reads like a weather report: some manufacturers available, some constrained, active-ingredient problems recurring. Generic price collapse requires many manufacturers delivering at the same time, so pharmacies can play them against each other. Intermittent supply means no one has to compete hard on price.
3. Demand went up while this was happening. Adult ADHD diagnoses and stimulant prescriptions rose sharply post-2020 (AJMC). Quotas were set for the old demand curve.
4. There's no substitute pressure inside the molecule. Vyvanse is the only prodrug amphetamine. If that's what's prescribed, the generic competes only with the brand and with other lisdexamfetamine makers, all of whom draw from the same constrained quota pool. And a shortage in one stimulant pushes demand sideways into the others, which have their own quota ceilings.
Documented ways people pay less
These are the mechanisms that exist on the record, for you to bring up with your prescriber, pharmacist, or insurer as applicable. None of it is advice.
Discount cards, and comparison-shopping between pharmacies. The $61–68 coupon prices on GoodRx are real and don't require insurance; they're just contracts pharmacies have already agreed to. The catch during a shortage: the cheapest pharmacy and the pharmacy that has your strength in stock may be different buildings.
Mark Cuban's Cost Plus Drugs won't work here, and knowing why saves you a search. Cost Plus does not fill prescriptions for controlled substances, which excludes every Schedule II stimulant, lisdexamfetamine included. People keep citing it as the fix. For this category it structurally can't be.
Insurance formulary exceptions and appeals. Plans publish exception processes. When a plan covers brand while refusing the generic (rebate math produces this regularly, however absurd it looks), or covers neither well, the documented route is a formulary-exception request or appeal filed with your prescriber's supporting statement. Tedious and paper-heavy. It also works often enough that plans are required to have the process.
Takeda's patient assistance program. Takeda's Help at Hand program provides brand Vyvanse at no cost to patients who meet income and insurance-status criteria. Eligibility is Takeda's call, and generic users generally aren't the target; it's a brand program for people who'd otherwise go without.
Strength flexibility exists, but it's a prescriber conversation. During the shortage, ASHP's listings have shown specific strengths going in and out of stock independently. Whether any of that is workable in your case gets decided in your prescriber's office and nowhere else, including here.
Where this goes
Slowly downward, on the evidence. The DEA raised the lisdexamfetamine quota about 22% in late 2025 and allowed further increases into 2026. Quota relief takes months to become capsules on shelves, and the ASHP entry is improving without being clear. The structural fix (many manufacturers shipping at once, fighting for shelf space) is closer than it was in 2023 and still hasn't arrived.
So check the coupon price before you hand over a card. Skipping that step can cost $250 a month.
Sources
- GoodRx: lisdexamfetamine prices and Vyvanse prices
- Forbes: FDA approves Vyvanse generics amid ADHD medication shortage (Aug 2023)
- Psychiatric Times: FDA approves first generics of lisdexamfetamine
- Federal Register: DEA adjustment to the 2025 aggregate production quota for lisdexamfetamine (Sept 2025)
- ASHP: lisdexamfetamine dimesylate capsules — current drug shortage
- AJMC: US ADHD stimulant shortage highlights growing challenges in adult treatment
- Cost Plus Drugs on controlled substances
- Takeda Help at Hand patient assistance